Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C25H27N3O5 |
Molar mass | 449.507 g·mol−1 |
3D model (JSmol) | |
| |
|
Iberdomide is an experimental thalidomide analog[1] that works as an cereblon E3 ligase modulator; it has a higher binding affinity than lenalidomide or pomalidomide. It is developed by Bristol Myers Squibb for various cancers[2][3][4][5][6][7][8] and was also tested in people with lupus.[9]